What You Should Know:
– CareYaya Health Technologies, a leading innovator in AI-powered solutions for the aging population, has launched MedaCareLLM, a new AI platform designed to assist individuals with dementia and Alzheimer’s disease.
– Integrated…
Continue Reading
Alzheimer’s disease (AD) is a global healthcare challenge lacking a simple and affordable detection method. We propose a novel deep learning framework, Eye-AD, to detect Early-onset Alzheimer’s Disease (EOAD) and Mild Cognitive Impairment (MCI)…
Continue Reading
What You Should Know:
– GE HealthCare announced today that its MIM Software has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a groundbreaking tool in the fight against Alzheimer’s disease.
–…
Continue Reading
The Remote Assessment of Disease and Relapse – Alzheimer’s Disease (RADAR-AD) consortium evaluated remote measurement technologies (RMTs) for assessing functional status in AD. The consortium engaged with the European Medicines Agency (EMA) to obtain…
Continue Reading
Dementia represents a significant global health challenge, with early screening during the preclinical stage being crucial for effective management. Traditional diagnostic biomarkers for Alzheimer’s Disease, the most common form of dementia, are limited by…
Continue Reading
Company’s Virtual Therapeutic Programs and Proprietary Risk Stratification Algorithm Support Proactive Detection of and Intervention for Cognitive Decline
Linus Health, a digital health company enabling early detection of cognitive impairment, Alzheimer’s, and other dementias, today…
What You Should Know: – OM1, the leader in real-world insights synthesis and evidence generation for life sciences supporting population and personalized data insights, evidence generation through advanced validated AI platforms, big deep clinical…
Continue Reading
What You Should Know:
– Verantos, the global leader in high-validity real-world evidence at scale, has launched its Alzheimer’s Disease Pragmatic Registry.
– This registry offers life sciences organizations rich and reliable data on patients with…
Continue Reading
What You Should Know:
– Eli Lilly’s Kisunla™ (donanemab-azbt) has been approved by the FDA as a treatment for adults in the early stages of Alzheimer’s disease (AD), including those with mild cognitive impairment (MCI)…
Continue Reading
What You Should Know:
– ALZpath, a leader in Alzheimer’s disease diagnostics, announced a licensing agreement with Roche for their innovative pTau217 antibody. This paves the way for a blood test to diagnose Alzheimer’s disease…
Continue Reading
